Clinical Trials

The purpose of this clinical study is to evaluate the safety and efficacy of the Micra Transcatheter Pacing System and to assess long term performance.

The purpose of this study is to investigate clinical outcomes from two current standard of care pain control procedures performed for patients undergoing pacemaker insertion.

Medtronic is sponsoring the Micra Continued Access (CA) study to provide continued access to the Micra System while the marketing application is under review by the Food and Drug Administration (FDA).

The purpose of this study is to evaluate the safety and effectiveness of the AveirTM Dual-Chamber (DR) Leadless Pacemaker (LP) system in patients indicated for a DDD(R) pacemaker to support regulatory approval for the Aveir DR LP system for DDD(R) pacing indications and the Aveir atrial LP for AAI(R) pacing indications.

Prospective, non-randomized, multi-center, international clinical study is designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a VVI(R) pacemaker.

The purpose is to conduct a study that determines the efficiency of FMDS in pre MRI screening for detecting cardiac implants in a Mayo Clinic environment.

The purpose of this study is to compare the safety and effectiveness of Edoxaban to Warfarin when used in patients with a non-valve related atrial fibrillation undergoing clinically indicated implantation or replacement of cardiovascular implantable electrical devices.

Patients with a patent foramen ovale in the setting of endocardially placed cardiac implantable electronic devices such as pacemakers, defibrillators, or resynchronization therapies are likely at higher risk for paradoxical embolic events from device lead thrombus. The investigators are conducting this study to determine if the anticoagulant medication Apixaban is more effective at reducing MRI detected brain lesions compared to placebo.

The aim of this study is to evaluate the relation of the acute pacing threshold (volts at ‘x’ pulse width) to the chronic pacing threshold of a pacemaker/ICD lead by studying the threshold during implantation at different pulse widths (eg. Twice of ‘x’, Three times of ‘x’).  

The purpose of this study is to evaluate the ability of the TYRX Absorbable Antibacterial Envelope to reduce major cardiovascular implantable electronic device infections through 12-months post-procedure following  generator replacement, upgrade, revision, or new CRT-D implant.

Participants enrolled in this study will have been diagnosed with patent foramen ovale (PFO) and have been scheduled to have a cardiovascular implantable electronic device (CIED) such as a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT) device implanted. A PFO is a condition when there is a hole in the septum (the wall separating the right and left sides) of the heart. The purpose of this study is to determine whether closing the PFO with the GORE® Cardioform Septal Occluder in people with an endocardial device leads reduces the risk of recurrent stroke or imaging-confirmed transient ischemic attack ...